NeoTract Announces Results from Five Real-World Studies Reaffirming Efficacy and Safety of UroLift® System Treatment for Enlarged Prostate
NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from five studies of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH).
“The real-world results from these studies of diverse patient populations on three continents reaffirm the sustained benefits of the UroLift System as an accepted standard of care treatment for patients with BPH,” said Dave Amerson, president of the NeoTract Interventional Urology business unit. “We are pleased that we continue to see results from real-world studies in line with our randomized pivotal study, demonstrating that the UroLift System is a safe and effective minimally invasive treatment that offers men long-term relief from the symptoms of BPH.”
Five Studies Show Significant Relief and Improved Quality of Life
with UroLift System
The “Real-World Experience” study, which enrolled 156 patients at the Norfolk & Norwich University Hospital in the U.K., compares outcomes of patients with BPH who received treatment with the UroLift System in a real-world setting to those seen in clinical studies.
The data, presented by Mark Rochester, M.D., consultant urological surgeon of Norfolk and Norwich University Hospitals NHS Foundation Trust U.K., demonstrates International Prostate Symptom Score (IPSS) improvement for patients treated with the UroLift System in a real-world setting, as well as improved quality of life (QoL) and peak flow rate (Qmax) at both the three and six-month follow up timepoints. At three months, patients experienced an average improvement of 10.0 points in IPSS, 2.2 points in QoL and 4.8 mL/s in Qmax. These results were statistically not different from those observed in the pivotal L.I.F.T. study.
“The excellent results of this large study were consistent with the pivotal L.I.F.T study,” said Dr. Rochester. “These outcomes demonstrate that the UroLift System can be used to treat patients with BPH in the real world safely and effectively.”
The “Does Size Matter?” study, which evaluates the UroLift System as a treatment for BPH in men with small and large prostate volumes, was presented by Gregory McMahon, D.O., urological surgery resident of Rowan University of Osteopathic Medicine (Stratford, N.J.), and Thomas Mueller, M.D., urologist of New Jersey Urology (Voorhees, N.J.). Both patient cohorts from this single-center study were treated in an office setting for a six-month period. Data from this study shows that men with small and large prostates experienced statistically significant improvement in symptoms and quality of life when treated for BPH with the UroLift System. At six months, mean IPSS decreased by 17.6 and 13.2, and QOL improved by 2.5 and 2.6 in the small and large prostate groups, respectively.
“Results from this study demonstrate the versatility of the UroLift System as an effective treatment for a wide range of patients and that it can be safely performed in an office setting. It is especially gratifying to see that results at an experienced center such as ours can meet or exceed those observed in the L.I.F.T. study,” said Dr. Mueller.
Three additional real-world studies were presented at the conference, each showing favorable results and improved outcomes for patients with BPH who received treatment with the UroLift System:
- The Management of Acute Urinary Retention Study, presented by Ashok J. Kar, M.D., director of robotic and minimally invasive surgery St. Joseph Hospital of Orange (Orange, Calif.), reviewed the outcomes of patients who were treated with the UroLift System for acute urinary retention due to BPH. All patients from this study had indwelling foley catheters in place and were treated exclusively in an office setting for an 18-month period. The results demonstrated that 90% of the patients became catheter-free within three months after treatment.
- Data presented by Campbell F. Bryson, M.D., chief urology resident of Yale New Haven Hospital (Princeton, N.J.), from a single-center, first-time, real-world study closely resembles results from the pivotal L.I.F.T trial, showing robust improvements in symptoms and quality of life for patients treated for BPH with the UroLift System.
- Results from an Early Experience study presented by Justin Chee, M.D., consultant urological surgeon of Western Health (Melbourne, Australia), show that patients treated for symptomatic BPH with the UroLift System in a public hospital setting experienced improvement in symptoms and quality of life with preserved sexual function.
About the UroLift System
The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Nearly 70,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System Prostatic Urethral Lift procedure is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at www.UroLift.com.
About NeoTract | Teleflex Interventional Urology
A wholly owned subsidiary of Teleflex Incorporated, the NeoTract Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose.
Mark Rochester and Thomas Mueller are paid consultants to NeoTract | Teleflex Interventional Urology.
MAC00843-02 Rev A
For Teleflex Incorporated
Treasurer and Vice President, Investor Relations
Nicole Osmer, 650.454.0504
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Panasonic Signs Joint Business Development Agreement with Startup Linkwiz to Enhance Welding Processes in Manufacturing17.6.2019 10:03:00 CEST | Pressemelding
On June 17, 2019, Panasonic Corporation (TOKYO: 6752) announced that it has signed a joint business development agreement with Linkwiz, Inc. — a startup company specializing in the development and sales of autonomous robotic system software and technical consulting — to develop solutions to enhance welding processes in the manufacturing field. The agreement is being undertaken by Panasonic’s Connected Solutions Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005360/en/ Yasu Higuchi, CEO of Panasonic's Connected Solutions Company (left) and Go Fukino, President of Linkwiz, Inc. (right) (Photo: Business Wire) Under its “Gemba Process Innovation” vision, Panasonic is expanding its B2B solutions business. “The ‘gemba,’ or physical site for frontline operations, is where value is generated and problems must be confronted,” explained Yasu Higuchi, CEO of the Connected Solutions Company. “By applying our 100-years of
Norsk Titanium & QuesTek Test Additive Titanium Alloy17.6.2019 10:00:00 CEST | Pressemelding
Building upon the collaboration announced at Farnborough in July 2018, Norsk Titanium (Norsk) has successfully printed QuesTek’s custom titanium wire in support of initial material properties testing. QuesTek thoroughly evaluated the microstructure and measured the properties in several heat-treated conditions including various combinations of stress relief and solution treatment. Superior performance versus Ti-6-4 has been demonstrated. The highest performance condition was a basic one-hour solution treatment where an average Ultimate Tensile Strength (UTS) of 147 ksi and an average elongation of 18% was measured. This represents an increase in both strength and elongation, while maintaining fatigue performance, over standard Ti-6Al-4V. “QuesTek’s high-performance titanium alloy provides an opportunity for Norsk’s customers to optimize components printed with Norsk Titanium’s RPD™ process and opens doors for new applications,” said Norsk Chief Technology Officer Carl Johnson. The typi
H.I.G. Europe to Acquire Polyurethane Systems Business from Covestro17.6.2019 08:05:00 CEST | Pressemelding
H.I.G. Capital, LLC ("H.I.G."), a leading global private equity investment firm with over €26 billion of equity capital under management, is pleased to announce that an affiliate has signed a definitive agreement to acquire the European Polyurethane Systems Business (the “Company”) in a carve-out transaction from Covestro AG. The transaction is subject to clearing by the relevant antitrust authorities with closing anticipated for the second half of 2019. The European Polyurethane Systems Business operates four systems houses in Germany, Denmark, the Netherlands and Spain. It employs approximately 250 full-time employees and generates annual sales of approximately €230 million. Systems houses develop and formulate tailor-made ready-to-use chemical blends for the production of a wide range of polyurethane products such as insulation materials, foams, shoe soles, and building materials. The Company serves a wide range of small- and mid-sized customers across Europe and will be led by Dr.
Appointment of Mark Wood as Chairman of HomeServe Labs17.6.2019 08:00:00 CEST | Pressemelding
HomeServe plc (“HomeServe”, “the Group”), the international home repairs and improvements business, is pleased to announce the appointment of Mark Wood CBE as non-Executive Chairman of HomeServe Labs, the unit within HomeServe that developed LeakBot. HomeServe Labs is the innovation arm of HomeServe which in 2016 launched LeakBot, a patented smart leak alarm that can detect leaks anywhere on a mains water system. Water leaks are one of the major causes of claims on home insurance policies across Western Europe and the US, and LeakBot is designed specifically to help insurance companies prevent water leak claims by catching the leaks early. Craig Foster, LeakBot CEO, said: "Mark Wood is a previous CEO of AXA and a veteran of the insurance industry. This experience will really benefit us as a B2B Insuretech. Mark is also a successful entrepreneur himself, and more recently added a huge amount of value to promising fintech start-ups like PensionBee. With Mark on board as our new Chairman,
TYAN Powers AI and HPC with 2nd Gen Intel® Xeon® Scalable Processor-based Server Platforms at ISC 201917.6.2019 08:00:00 CEST | Pressemelding
TYAN®, an industry-leading server platform design manufacturer and a MiTAC Computing Technology Corporation subsidiary, is showcasing its new 2nd gen Intel® Xeon® Scalable processor-based platforms that are optimized for predictive analytics, machine learning, and HPC applications at ISC 2019 from June 17-19 at Messe Frankfurt, booth C-1250. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005020/en/ TYAN's Thunder HX Lineup Designed for AI Optimization and HPC Revolution (Photo: Business Wire) “The most demanding workloads including HPC, AI deep learning, data analytics, and multi-cloud infrastructure require maximum performance across compute, memory, storage, and network resources, “said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “2nd gen Intel Xeon Scalable processors provide a powerful foundation for TYAN server platforms that enables us to deliver performance enhanceme
Norsk Titanium Announces Larger Capacity Rapid Plasma Deposition™ (RPD™) Machine17.6.2019 08:00:00 CEST | Pressemelding
Officials with Norsk Titanium (Norsk) announced today the company has designed and is currently building a larger-scale Rapid Plasma Deposition™ (RPD™) machine. This new machine enables manufacturing of larger, more complex aircraft and engine components, at faster print speeds. The new RPD™ machine, the G-IVL, will use the same advanced RPD™ technology of Norsk’s current additive manufacturing process. Norsk’s patented RPD™ technology and equipment utilizes proprietary process controls to melt titanium wire with plasma torches, in an argon environment to produce near-net shape components for airframe and aircraft engine applications. The Norsk G-IVL machine will expand the printing envelope to 190cm by 40cm by 60cm. It will print double-sided, as well as single-sided components, of complex geometries and deposit material in excess of 8kg per hour. The resultant component will have the material qualities equivalent to forgings. “The G-IVL machine will significantly expand Norsk’s capab